Syndax Pharmaceuticals, Inc. (SNDX)
9.46
-0.09
(-0.94%)
USD |
NASDAQ |
Nov 10, 16:00
9.46
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Cash from Operations (Annual) : -322.98M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -322.98M |
| December 31, 2024 | -274.90M |
| December 31, 2023 | -160.60M |
| December 31, 2022 | -133.68M |
| December 31, 2021 | 29.13M |
| December 31, 2020 | -71.26M |
| December 31, 2019 | -50.61M |
| December 31, 2018 | -68.53M |
| Date | Value |
|---|---|
| December 31, 2017 | -47.37M |
| December 31, 2016 | -35.16M |
| December 31, 2015 | -2.428M |
| December 31, 2014 | -14.39M |
| December 31, 2013 | -7.295M |
| December 31, 2012 | -9.284M |
| December 31, 2011 | -10.02M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Emergent BioSolutions, Inc. | 170.60M |
| Incyte Corp. | 1.413B |
| Vertex Pharmaceuticals, Inc. | 3.631B |
| Travere Therapeutics, Inc. | 37.78M |